Antibody-drug conjugates (ADCs), such as human epidermal growth factor receptor 2 (HER-2), nectin cell adhesion molecule 4 (Nectin-4), and epidermal growth factor receptor (EGFR)-targeted ADC drugs, have been explored recently and have been shown to be effective in several human cancers [7–9]. This evidence concerns the gene ERBB2 and cancer.